Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Affimed N.V.    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/06/2020 07/07/2020 07/08/2020 07/09/2020 07/10/2020 Date
4.34(c) 4.39(c) 4.58(c) 4.6(c) 4.41(c) Last
1 287 727 2 639 159 736 346 2 148 757 1 172 714 Volume
-5.03% +1.15% +4.33% +0.44% -4.13% Change
More quotes
Financials
Sales 2020 20,1 M 22,8 M 22,8 M
Net income 2020 -39,1 M -44,3 M -44,3 M
Net Debt 2020 - - -
P/E ratio 2020 -7,82x
Yield 2020 -
Sales 2021 24,2 M 27,4 M 27,4 M
Net income 2021 -12,9 M -14,6 M -14,6 M
Net Debt 2021 - - -
P/E ratio 2021 -22,9x
Yield 2021 -
Capitalization 298 M 336 M 337 M
Capi. / Sales 2020 14,8x
Capi. / Sales 2021 12,3x
Nbr of Employees 137
Free-Float 87,7%
More Financials
Company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28... 
Sector
Biotechnology & Medical Research
Calendar
08/04 | 11:00amAktionärsversammlung
More about the company
Surperformance© ratings of Affimed N.V.
Trading Rating : Investor Rating :
More Ratings
Latest news on AFFIMED N.V.
07/10Affimed Announces Annual General Meeting of Shareholders
GL
06/23Affimed Reports First Quarter 2020 Financial Results and Operational Progress
GL
06/22Affimed Announces Presentation of Data on Genentech's RO7297089 and AFM24, Bo..
GL
06/17Affimed Announces Successful Completion of First Dose Cohort in First-in-Huma..
GL
06/16Affimed to Report First Quarter 2020 Financial Results & Corporate Update Jun..
GL
06/11Affimed Announces Appointment of Angus Smith as Chief Financial Officer
GL
05/29Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 ..
GL
05/28Affimed to Present at the Jefferies Virtual Healthcare Conference
GL
05/15Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform A..
GL
04/28Affimed Reports 2019 Financial Results and Recent Operational Progress
GL
04/16Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/..
GL
04/02Affimed Provides COVID-19-Related Business Update and Announces Full Year 201..
GL
04/01Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell En..
GL
03/26Affimed Announces Participation at Upcoming Virtual Investor Conferences
GL
03/17Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scien..
GL
More news
News in other languages on AFFIMED N.V.
07/10Affimed Announces Annual General Meeting of Shareholders
06/23Affimed Reports First Quarter 2020 Financial Results and Operational Progress
06/22Affimed Announces Presentation of Data on Genentech's RO7297089 and AFM24, Bo..
06/17Affimed Announces Successful Completion of First Dose Cohort in First-in-Huma..
06/16Affimed to Report First Quarter 2020 Financial Results & Corporate Update Jun..
More news
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 6,27 €
Last Close Price 3,90 €
Spread / Highest target 126%
Spread / Average Target 60,7%
Spread / Lowest Target 24,3%
EPS Revisions
Managers
NameTitle
Adolf Hoess Chief Executive Officer
Thomas O. Hecht Chairman-Supervisory Board
Wolfgang Fischer Chief Operating Officer
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
AFFIMED N.V.60.95%336
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955